1. Circulating proteins to predict adverse COVID-19 outcomes
- Author
-
Edgar Gonzalez-Kozlova, David R. Morrison, Branka Vulesevic, Nofar Kimchi, Robert Marvin, Maik Pietzner, Zaman Afrasiabi, Kimberly Argueta, Louis Petitjean, Naomi Duggan, Ryan Thompson, Meriem Bouab, Manishkumar Patel, Kevin Tuballes, Ieisha Scott, J. Brent Richards, Mario A. Cedillo, Nicole W. Simons, Jocelyn Harris, Tala Abdullah, Claudia Langenberg, Danielle Henry, Vincenzo Forgetta, Daniel Kaufmann, Madeleine Durand, Chen-Yang Su Mr., Michael A Hinterberg, Elsa Brunet-Ratnasingham, Celia M. T. Greenwood, Miriam Merad, Wonseok Jeon, Alexander W. Charney, Sacha Gnjatic, Noam D. Beckmann, Xiaoqing Xue, Nicolas Zaki, Julia Carrasco-Zanini, Diane Marie Del Valle, Joelle Pineau, Esther Cheng, Tomoko Nakanishi, Olumide Adeleye, Kai Nie, Chantal DeLuca, Konstantinos Mouskas, Thomas U. Marron, Marc Afilalo, Guillaume Butler-Laporte, Yiheng Chen, Yossi Farjoun, Yara Moussa, Vincent Mooser, Eric E. Schadt, Clare Paterson, Noor Almamlouk, Chris Tselios, Nathalie Brassard, Sirui Zhou, Hui Xie, Ephraim Kenigsberg, Nardin Rezk, Seunghee Kim-Schulze, Laetitia Laurent, Charlotte Guzman, Erwin Schurr, and Joanthan Afilalo
- Subjects
Oncology ,medicine.medical_specialty ,Receiver operating characteristic ,Coronavirus disease 2019 (COVID-19) ,business.industry ,medicine.medical_treatment ,Disease progression ,Age and sex ,Cytokine ,Internal medicine ,Cohort ,Medicine ,Generalizability theory ,business ,Predictive modelling - Abstract
Predicting COVID-19 severity is difficult, and the biological pathways involved are not fully understood. To approach this problem, we measured 4,701 circulating human protein abundances in two independent cohorts totaling 986 individuals. We then trained prediction models including protein abundances and clinical risk factors to predict adverse COVID-19 outcomes in 417 subjects and tested these models in a separate cohort of 569 individuals. For severe COVID-19, a baseline model including age and sex provided an area under the receiver operator curve (AUC) of 65% in the test cohort. Selecting 92 proteins from the 4,701 unique protein abundances improved the AUC to 88% in the training cohort, which remained relatively stable in the testing cohort at 86%, suggesting good generalizability. Proteins selected from different adverse COVID-19 outcomes were enriched for cytokine and cytokine receptors, but more than half of the enriched pathways were not immune-related. Taken together, these findings suggest that circulating proteins measured at early stages of disease progression are reasonably accurate predictors of adverse COVID-19 outcomes. Further research is needed to understand how to incorporate protein measurement into clinical care.
- Published
- 2021